San Diego, CA, December 04, 2013 --(PR.com
)-- Harald Petry, Chief Scientific Officer of uniQure B.V., will give a featured presentation on evolving regulatory challenges and requirements for drug development at the Inaugural Cell and Gene Therapy Conference on February 20-21, 2014 in San Diego, CA by GTC.
uniQure’s Glybera® is the first gene therapy approved by the European Commission and by regulatory authorities in the Western world. It is the first medication approved for patients with Lipoprotein Lipase Deficiency, a rare metabolic disorder.
Dr. Petry joined uniQure’s predecessor company AMT in May 2007 as Director of Research and Development. He has worked in the area of gene therapy for more than 15 years and has extensive experience in pharmaceutical research. After his PhD, he built up a career in academic research and subsequently in the international biopharmaceutical industry. Prior to joining uniQure, he worked at Jenapharm GmbH (Germany), and Berlex Biosciences (US) in different functions with increasing managerial and leadership responsibility.
Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, it is important to stay up-to-date with the evolving regulatory challenges and pre-clinical requirements for drug development and discovery. This meeting brings together experts from industry and academia to discuss the development and applications of cell and gene therapy as well as strategies and challenges for commercialization.
This conference is also part of the Future Biotech Summit 2014, which consists of this conference, and two other additional co-located conferences:
Cell & Gene Therapy
2nd Orphan Drugs Research & Commercialization
Ubiquitin Research & Drug Discovery
For more information, please visit www.gtcbio.com